Vicarious Surgical (RBOT) Registration Filing summary

Company overview and business model

• Develops advanced miniaturized robotics, computer science, and 3D visualization for a new category of intelligent, affordable, single-port surgical robots for minimally invasive surgery.

• Targets over 45 million annual soft tissue procedures globally, with initial focus on ventral hernia repair.

• System designed to address limitations of open and current robotic surgery, offering improved dexterity, lower capital costs, and easier adoption.

• Platform not yet FDA authorized; first clinical-ready system expected by mid-2026, with human trials anticipated in 2027.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates is approximately $26.74 million as of October 15, 2025.

• Sold $5,865,000 of securities in the prior twelve months under Form S-3 eligibility rules.

• Net tangible book value as of September 30, 2025, was $14.1 million, or $2.36 per share.

• After the offering, as adjusted net tangible book value would be $16.9 million, or $2.3875 per share, with immediate dilution of $0.3225 per share to new investors at an assumed price of $2.71.

Use of proceeds and capital allocation

• Proceeds intended for general corporate purposes, including working capital, capital expenditures, R&D, and clinical trial expenditures.

• May use a portion for acquisitions or strategic investments, though no current plans exist.

• Pending use, proceeds will be invested in short-term, investment-grade, interest-bearing instruments and U.S. government securities.